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THIEME

Case Report
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Abstract

Keywords
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(OUD)
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► neonatal opioid
withdrawal syndrome
(NOWS)

Objective To examine the relationship between antepartum buprenorphine dose for
medication-assisted treatment (MAT) of opioid use disorder (OUD) and incident
neonatal opioid withdrawal syndrome (NOWS).
Study Design We performed a prospective cohort study of pregnant women with a
singleton gestation diagnosed with OUD and receiving buprenorphine for MAT at a
tertiary care academic institution from July 2015 to January 2017. We divided the study
cohort into two groups—pregnancies with versus without NOWS. Substance abuse
patterns in pregnancy, maternal, and neonatal clinical outcomes were compared.
Results The incidence of NOWS was 31.11% (n ¼ 28/90) in our study cohort. Pregnancies
with NOWS had a signiﬁcantly higher rate of benzodiazepine positive urine tests and
number of positive urine drug screen (UDS) results for illicit opioids. The group without
NOWS had signiﬁcantly higher number of patients with an appropriate UDS result at
delivery through postpartum. Rates of neonatal intensive care unit (NICU) admission,
length of NICU stay, and maximum Finnegan score were signiﬁcantly higher in the group
with NOWS. Neither the initial (10.6  5.2 versus 10.3  4.8 mg, p ¼ 0.80) nor the ﬁnal
buprenorphine doses (13.3  5.1 versus 13.0  4.6 mg, p ¼ 0.81) were signiﬁcantly
different between study groups.
Conclusion The occurrence of NOWS was not related to buprenorphine dose used
for MAT.

Opioid use disorder (OUD) is increasingly recognized as a
national public health epidemic in the United States, leading
not only to adverse perinatal outcomes, but also negative
effects on childhood neurodevelopment.1–5 The problem is
further compounded by the increasing burden of healthcare
costs associated with treatment of neonates exposed to

opioids in utero who then experience neonatal opioid withdrawal syndrome (NOWS).6,7 Management algorithms of
OUD in pregnancy have traditionally hinged on the use of
methadone as the agent of choice for pharmacotherapy—
either constituted along the lines of a methadone “taper” or
maintaining a steady state of methadone as a form of
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medication-assisted treatment (MAT).8–10 However, the use
of methadone for MAT during pregnancy also carries the risk
of fetal exposure in utero, manifesting as NOWS, also known
as neonatal abstinence syndrome (NAS).10,11 Affected neonates exhibit a clinical proﬁle characterized by hyperirritability, agitation, and central and/or autonomic nervous
system dysfunction often necessitating intervention with
pharmacologic therapy. This in turn leads to prolonged
inpatient hospitalization for the neonate and the need for
continued outpatient surveillance.10–15 Recently, attention
has shifted toward the use of buprenorphine as an agent of
choice for MAT of OUDs in pregnancy. Buprenorphine administration was initially targeted toward women who could be
followed-up at longer intervals, representing a higher level of
medication adherence and compliance, without the need for
daily monitoring (as is the case with methadone). Buprenorphine treatment in an ofﬁce-based setting allows women to
have prescriptions for their medications, longer intervals
between visits, and unsupervised dosing representing a
model of care consistent with other chronic medical
illnesses, in contrast to methadone treatment that requires
more intensive monitoring with daily supervised dosing for
the ﬁrst 90 days of treatment that sometimes becomes a
barrier to treatment entry.16–19 Importantly, maternal treatment with buprenorphine in pregnancy has been shown to
have similar efﬁcacy as methadone while also representing a
safe and convenient option for outpatient management by
allowing for prescribing through certiﬁed physician ofﬁces
rather than daily attendance at methadone clinics.16,18,20,21
While buprenorphine is generally accepted in pregnancy as a
safe alternative to methadone for MAT, the extent to which
buprenorphine dose correlates with the risk of NOWS remains incompletely understood, with some studies supporting a dose–response relation and others not.1,17,20–22
The objective of our study was to examine the relationship
between antepartum buprenorphine dose among pregnant
women undergoing MAT for OUD and incident NOWS.

Methods
The study was approved by the Institutional Review Board
(IRB) at the University of Kentucky. Women were recruited
from the Perinatal Assistance and Treatment Home (PATHways) Program at the University of Kentucky Polk Dalton
clinic—an outpatient treatment program that includes group
prenatal and postpartum care, MAT, and supportive services
for high-risk women throughout Kentucky. We prospectively
recruited and followed a cohort of pregnant women with a
well-documented history of OUD, receiving prenatal care at a
tertiary teaching institution from July 2015 to January 2017.
Inclusion criteria included: (1) current diagnosis of opioid
dependence with participation in the buprenorphine treatment program; (2) less than 30 weeks with a singleton
gestation; and (3) age 18 to 49 years old. Women were
excluded if they had current prisoner status, current severe
mental illness (e.g., bipolar disorder with current mania,
current suicidal ideation), or alcohol or sedative/hypnotic
dependence that required medical intervention.
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All patients received buprenorphine as the agent of choice
for MAT of OUD, which was prescribed by waivered
(X-licensed) maternal fetal medicine physicians with advanced training and licensure for buprenorphine administration. Buprenorphine dosing was once daily after initial
buprenorphine induction, which veriﬁed objective withdrawal with the Clinical Opiate Withdrawal Scale (COWS).
Medication adjustments were individualized for each patient
based on healthcare provider clinical judgment, factoring
in patient response and medication adherence. Patients
received no more than a 2-week prescription at any given
point in time. All patients received buprenorphine in the
form of the commercially marketed generic formulation—
Subutex (Reckitt Benckiser Pharmaceuticals, Inc, Richmond,
Virginia), containing only buprenorphine, without naloxone.
Pregnant patients with ongoing illicit drug use, e.g., as
determined by self-report and/or urine drug testing, were
managed by a customized approach centered upon escalation of care. For example, patients received increased face-toface counseling with providers having subspecialty training
in maternal fetal medicine, mental health, and addiction
medicine. This was accompanied by closer follow-up and
surveillance monitoring with visits ranging from once to
thrice weekly. Patients were followed through delivery until
6 weeks postpartum. Patients underwent serial urine drug
screens (UDS) at each prenatal visit, upon admission into the
Labor & Delivery Unit and every postpartum visit. MAT was
continued in all cases through the study period. Upon
completion of the 6-week postpartum period, maternal
and neonatal clinical outcomes data were abstracted through
a review of their respective medical records. Data pertaining
to maternal demographics, patterns of antenatal substance
abuse, and incident pregnancy comorbidities were obtained
from a thorough review of their outpatient electronic medical record. Labor and delivery–related outcomes were ascertained through a review of the inpatient electronic medical
record system. The diagnosis of NOWS requiring pharmacologic management was conﬁrmed based on documentation
in the neonatal electronic medical record system. These cases
were managed as per standardized institutional neonatal
intensive care unit (NICU) protocols that used a modiﬁed
Finnegan scale for scoring neonates for opioid withdrawal,
also known as the MOTHER NAS scale.1,14 In this system,
scoring is done for any infant chronically exposed to opioids
in utero or who has demonstrated signs of signiﬁcant withdrawal. Scoring is performed every 3 to 4 hours and changed
to every 6 to 8 hours once the infant is stable. Pharmacologic
therapy was initiated when three consecutive scores were
>8 or two consecutive scores were >12. We divided the
study cohort into two groups—that is, pregnancies with and
without incident NOWS requiring pharmacotherapy.
Details of maternal substance abuse patterns during pregnancy, as well as maternal and neonatal clinical outcomes, were
compared across these two groups, using the two-sample t-test
or Mann–Whitney U test for continuous data, as appropriate,
and the chi-square test of association or Fisher’s exact test for
categorical data. All statistical analyses were performed using
SAS version 9.4; an α level of 0.05 was used throughout.
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Results
We recruited a total of 96 patients receiving buprenorphine
for treatment of OUD in pregnancy. Of these, 90 patients
delivered at our tertiary teaching hospital and were therefore
available for follow-up of maternal and neonatal outcomes
(the rest delivered at an outside hospital and hence their
delivery outcomes data and neonatal data were unavailable
and excluded from analyses). The incidence of NOWS was
noted to be 31.11% in our cohort (n ¼ 28). Demographic
characteristics (►Table 1) were similar among the group of
patients with and without incident NOWS. Interestingly,
patterns of tobacco use during pregnancy (including smoking before and during pregnancy) as well as the use of
smoking cessation treatment with nicotine replacement
therapy were also similar in both groups (p > 0.05).
Substance abuse characteristics between the two groups
are compared in ►Table 2. Patients in each group underwent
buprenorphine induction at 20 weeks gestation. Routes of
substance use or age at initiation of substance misuse did not
differ between the two groups. The group with NOWS was
noted to have a signiﬁcantly higher rate of benzodiazepine
abuse—as noted in their history of substance abuse as well as
detection at initial UDS. Signiﬁcantly, pregnancies with
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NOWS were also noted to have a signiﬁcantly higher number
of positive UDS results (for illicit substances) over the course
of pregnancy. Most importantly, neither the initial nor the
ﬁnal buprenorphine dose at delivery was signiﬁcantly different between the two groups.
►Table 3 compares maternal pregnancy and delivery
outcomes as well as postpartum course among the two study
groups. There were no signiﬁcant differences in the incidence of adverse perinatal outcomes between the study
groups. However, the group without NOWS had a signiﬁcantly higher number of patients with an appropriate UDS
result (i.e., only positive for buprenorphine) at delivery, 2, 4,
and 6 weeks postpartum. Rates of NICU admission, length of
NICU stay, and maximum Finnegan score were signiﬁcantly
higher in the group with NOWS, as seen in ►Table 4. The
remainder of the neonatal outcomes under evaluation failed
to reach statistical signiﬁcance.

Discussion
Within our clinical cohort, the occurrence of NOWS was not
related to the buprenorphine dose used for MAT of OUD in
pregnancy. There were no signiﬁcant differences in the initial
or ﬁnal buprenorphine dose in pregnancies with and without

Table 1 Demographic characteristics
Total sample
(N ¼ 90)
Mean  SD,
Median (IQR)
or n (%)

NOWS
(n ¼ 28)
Mean  SD,
Median (IQR)
or n (%)

Non-NOWS
(n ¼ 62)
Mean  SD,
Median (IQR)
or n (%)

p

28.8  4.6

28.6  5.1

28.9  4.4

0.79

Gravidity

3 (2–5)

3 (2–4.5)

3 (2–5)

0.98

Parity (living)

2 (1–3)

2 (1–2.5)

2 (1–3)

0.86

Living children parent custody

0 (0–1)

0 (0–0.5)

0 (0–1.0)

0.29

BMI at start of care

25.1  4.6

25.2  4.5

25.0  4.6

0.82

White/non-Hispanic

83 (92.2%)

25 (89.3%)

58 (93.6%)

0.67

Other

7 (7.8%)

3 (10.7%)

4 (6.4%)

Yes

33 (37.1%)

10 (37.0%)

23 (37.1%)

No

56 (62.9%)

17 (63.0%)

39 (62.9%)

Employed

14 (15.6%)

1 (3.6%)

13 (21.0%)

Unemployed

76 (84.4%)

27 (96.4%)

49 (79.0%)

Yes

20 (24.4%)

4 (15.4%)

16 (28.6%)

No

62 (75.6%)

22 (84.6%)

40 (71.4%)

Yes

82 (92.1%)

26 (92.9%)

56 (91.8%)

No

7 (7.9%)

2 (7.1%)

8 (8.2%)

Age

Race/ethnicity

Partnered status
0.99

Employment
0.056

Nicotine replacement
0.20

Using tobacco at delivery
0.86

Abbreviations: BMI, body mass index; IQR, interquartile range; NOWS, neonatal opioid withdrawal syndrome; SD, standard deviation.
Note: p-Values represent comparison between the NOWS and non-NOWS group.
American Journal of Perinatology Reports

Vol. 7

No. 4/2017

e217

e218

Buprenorphine Dose and Neonatal Opioid Withdrawal Syndrome

Chavan et al.

Table 2 Details of substance abuse patterns
Total sample
(N ¼ 90)
Mean  SD,
Median (IQR)
or n (%)

NOWS
(n ¼ 28)
Mean  SD,
Median (IQR)
or n (%)

Non-NOWS
(n ¼ 62)
Mean  SD,
Median (IQR)
or n (%)

p

Gestational age at program initiation

21.5  8.4

23.3  8.4

20.6  8.4

0.17

Gestational age at buprenorphine induction

21.2  8.1

22.1  7.6

20.8  8.3

0.53

Age at ﬁrst substance abuse

18.7  5.0

18.5  5.9

18.8  4.4

0.80

Opioids

88 (97.8%)

28 (100.0%)

60 (96.8%)

>0.99

Methamphetamine

17 (18.9%)

7 (25.0%)

10 (16.1%)

0.32

Cocaine

25 (27.8%)

9 (32.1%)

16 (25.8%)

0.53

Benzodiazepines

31 (34.4%)

13 (46.4%)

18 (29.0%)

0.11

THC

54 (60.0%)

19 (67.9%)

35 (56.5%)

0.31

History of substance abuse

Route of substance abuse
Oral

85 (94.4%)

26 (92.9%)

59 (95.2%)

0.65

Intravenous

43 (47.8%)

16 (57.1%)

27 (43.6%)

0.23

Intranasal

68 (75.6%)

26 (92.9%)

42 (67.7%)

0.015

Opioids

34 (37.8%)

11 (39.3%)

23 (37.1%)

0.84

Methamphetamine

7 (7.8%)

3 (10.7%)

4 (6.5%)

0.67

Cocaine

10 (11.1%)

6 (21.4%)

4 (6.5%)

0.065

Benzodiazepines

16 (17.8%)

10 (35.7%)

6 (9.7%)

0.006

THC

27 (30.0%)

12 (42.9%)

15 (24.2%)

0.074

Positive UDS (% yes)

69 (76.7%)

27 (96.4%)

42 (67.7%)

0.003

Number of positive UDS total
(any substance other than buprenorphine)

4 (1–8)

9 (6–12.5)

2 (0–6)

<0.001

Positive UDS illicit opioids (% yes)

48 (53.3%)

23 (82.1%)

25 (40.3%)

<0.001

Number of positive UDS total – illicit opioids

1 (0–3)

2 (1–4)

0 (0–2)

<0.001

Initial buprenorphine dose

10.4  4.9

10.6  5.2

10.3  4.8

0.80

Final buprenorphine dose

13.1  4.7

13.3  5.1

13.0  4.6

0.81

Substances positive on initial UDS

Abbreviations: IQR, interquartile range; NOWS, neonatal opioid withdrawal syndrome; SD, standard deviation; THC, tetrahydrocannabinol; UDS,
urine drug screen.
Note: p-Values represent comparison between the NOWS and non-NOWS group.

incident NOWS. The incidence of NOWS in our cohort was
noted to be 31.11%, which is lower than the reported rates in
several other contemporary studies.1,23,24 The incidence of
NOWS requiring treatment in the setting of maternal buprenorphine use has been variably reported from 22 to 63%.21–26
Interestingly, several of these studies have focused on comparing the impact of methadone versus buprenorphine on
incident NOWS. Patterns of tobacco use, including ongoing
smoking and smoking cessation/nicotine replacement therapy, were similar among patients with and without incident
NOWS in our study. This is in contrast to studies which show
a relationship between maternal tobacco exposure and an
increased likelihood of developing NOWS among women
undergoing MAT for OUD in pregnancy.27,28
In a double-blind randomized controlled trial called the
Maternal Opioid Treatment: Human Experimental Research
American Journal of Perinatology Reports

Vol. 7

No. 4/2017

(MOTHER) project, Jones et al compared neonatal outcomes
among women undergoing MAT with methadone versus buprenorphine at eight different international sites. They found
that neonates born to mothers receiving buprenorphine for
MAT had a signiﬁcantly shorter duration of treatment of NOWS
and required signiﬁcantly lesser morphine for treatment.1
However, the total number of neonates receiving treatment
for NOWS was not statistically different in the two groups in
this study. The incidence of treatment requiring NOWS in the
group receiving buprenorphine in the MOTHER study was 47%.
Globally, few other studies have delved into the evaluation of
methadone versus buprenorphine and consequent development of NOWS. In a nonrandomized population-based Swedish
study, Kakko et al compared neonatal outcomes among prospectively followed pregnancies exposed to buprenorphine
with retrospectively analyzed pregnancies exposed to
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Table 3 Maternal pregnancy course, delivery, and postpartum outcomes
Total sample
(N ¼ 90)
n (%)

NOWS
(n ¼ 28)
n (%)

Non-NOWS
(n ¼ 62)
n (%)

p

Preterm labor

11 (12.2%)

2 (7.1%)

9 (14.5%)

0.49

Preeclampsia

5 (5.7%)

1 (3.6%)

4 (6.7%)

>0.99

Gestational hypertension

7 (7.8%)

1 (3.6%)

6 (9.7%)

0.43

Diabetes

6 (6.7%)

4 (14.3%)

2 (3.2%)

0.073

IUGR

10 (11.1%)

1 (3.6%)

9 (14.5%)

0.16

Oligohydramnios

1 (1.1%)

0 (0.0%)

1 (1.6%)

>0.99

Polyhydramnios

1 (1.1%)

1 (3.6%)

0 (0.0%)

0.31

Hepatitis C

42 (47.2%)

14 (50.0%)

28 (45.9%)

0.72

RPR positivity

1 (1.1%)

1 (3.6%)

0 (0.0%)

0.31

Cholestasis

2 (2.9%)

2 (8.7%)

0 (0.0%)

0.11

Primary cesarean section

10 (11.1%)

3 (10.7%)

7 (11.3%)

0.78

Repeat cesarean section

29 (32.2%)

11 (39.3%)

18 (29.0%)

Assisted vaginal

2 (2.2%)

1 (3.6%)

1 (1.6%)

Spontaneous vaginal

48 (53.3%)

13 (46.4%)

35 (56.5%)

VBAC

1 (1.1%)

0 (0.0%)

1 (1.6%)

Mode of delivery

Induction of labor
Yes

24 (27.3%)

6 (22.2%)

18 (29.5%)

No

64 (72.7%)

21 (77.8%)

43 (70.5%)

0.48

Augmentation of labor
Yes

20 (27.4%)

6 (26.1%)

14 (28.0%)

No

53 (72.6%)

7 (73.9%)

36 (72.0%)

0.86

Yes

59 (67.8%)

13 (46.4%)

46 (78.0%)

No

20 (23.0%)

13 (46.4%)

7 (11.9%)

Not done

8 (9.2%)

2 (7.2%)

6 (10.2%)

UDS appropriate at 2 wk postpartum (n ¼ 82)

60 (73.2%)

10/24 (41.7%)

50/58 (86.2%)

<0.001

UDS appropriate at 4 wk postpartum (n ¼ 76)

54 (71.1%)

12/23 (52.2%)

42/53 (79.3%)

0.017

UDS appropriate at 6 wk postpartum (n ¼ 58)

33 (56.9%)

8/21 (38.1%)

25/37 (67.6%)

0.029

Appropriate UDS at delivery
0.002

Abbreviations: IUGR, intrauterine growth restriction; NOWS, neonatal opioid withdrawal syndrome; RPR, rapid plasma reagin; UDS, urine drug
screen; VBAC, vaginal birth after cesarean section.
Note: p-Values represent comparison between the NOWS and non-NOWS group.

methadone. In this study, treatment with buprenorphine
offered the advantage of lower incidence of NOWS requiring
pharmacological treatment, as well as shorter length of hospital stay for affected neonates.23 In a similar study of a Norwegian national clinical cohort of 139 mother–neonate couplets,
Welle-Strand et al compared neonatal outcomes among patients receiving methadone versus buprenorphine for MAT
during pregnancy. They found that the number of neonates
that received treatment for NOWS was not signiﬁcantly different between both groups as was the case with the peak
Finnegan score and the length of treatment.24 Signiﬁcantly,
in a subgroup analysis, this group found that the concomitant
benzodiazepines abuse during pregnancy while on MAT was

associated with longer duration of treatment for NOWS. These
ﬁndings parallel our observation wherein pregnancies affected
by NOWS appear to have a signiﬁcantly higher rate of benzodiazepine abuse. This also points toward the contributory role
of concomitant illicit drug use (particularly benzodiazepine
abuse) on possibly altering neonatal outcomes among pregnant
women receiving MAT for OUD.
In a secondary analysis of the MOTHER study, Jones et al
examined the relationship between buprenorphine at delivery
among patients undergoing MAT and neonatal outcomes
including NOWS.29 The authors found no relationship between
buprenorphine dose and any of the neonatal outcomes under
study, including incident NOWS, gestational age at delivery,
American Journal of Perinatology Reports
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Table 4 Neonatal course
Total sample
(N ¼ 90)
Mean  SD,
Median (IQR)
or n (%)

NOWS
(n ¼ 28)
Mean  SD,
Median (IQR)
or n (%)

Non-NOWS
(n ¼ 62)
Mean  SD,
Median (IQR)
or n (%)

p

38.0  2.2

38.5  1.1

37.8  2.6

0.17

Male

43 (48.9%)

15 (53.6%)

32 (53.3%)

0.55

Female

45 (51.1%)

13 (46.4%)

28 (46.7%)

<7

9 (10.1%)

4 (14.8%)

5 (8.1%)

7

80 (89.9%)

23 (85.2%)

57 (91.1%)

<7

6 (6.7%)

4 (14.8%)

2 (3.2%)

7

83 (93.3%)

23 (85.2%)

60 (96.8%)

Gestational age at delivery
Baby gender

APGAR score at 1 min
0.45

APGAR score at 5 min
0.066

Birth weight (g)

2804.3  491.8

3013.6  350.4

2709.7  519.0

0.002

Birth weight percentile

27.6  20.3

38.5  23.2

23.4  17.5

0.003
0.049

Mode of feeding
Breastfeeding

17 (18.9%)

2 (7.1%)

15 (24.2%)

Bottle

48 (53.3%)

20 (71.4%)

28 (45.2%)

Combination

25 (27.8%)

6 (21.4%)

19 (30.7%)

NICU admission

42 (46.7%)

28 (100.0%)

14 (22.6%)

<0.001

Days in NICU

6.5 (0–17)

16.5 (12.5–23.5)

0 (0–5.5)

<0.001

Highest Finnegan score

11 (8–14)

14 (13–15)

9 (7–11)

<0.001

Maximum morphine dose

0.15 (0.14–0.18)

Total number of morphine doses

97 (69–152)

Infant UDS positive for buprenorphine

68 (80.0%)

17 (63.0%)

51 (87.9%)

0.007

Infant UDS positive for norbuprenorphine

75 (88.2%)

22 (81.5%)

53 (91.4%)

0.19

Maternal screen positive for buprenorphine

51 (58.6%)

14 (51.9%)

37 (67.7%)

0.39

Maternal screen positive for norbuprenorphine

74 (85.1%)

20 (74.1%)

54 (90.0%)

0.10

Breastfeeding at discharge

31 (34.8%)

4 (14.3%)

27 (44.3%)

0.006

Abbreviations: APGAR score, Appearance, Pulse, Grimace, Activity, and Respiration score; IQR, interquartile range; NICU, neonatal intensive care
unit; NOWS, neonatal opioid withdrawal syndrome; SD, standard deviation; UDS, urine drug screen.
Note: p-Values represent comparison between the NOWS and non-NOWS group. All bold represents statistical signiﬁcance at the 95% conﬁdence level.

Appearance, Pulse, Grimace, Activity, and Respiration (APGAR)
scores at 1 and 5 minute, neonatal head circumference, length
and birth weight at birth, amount of morphine needed to treat
NOWS, duration of treatment, and length of neonatal hospital
stay. Based on these ﬁndings, this group failed to support the
occurrence of a dose–response relationship between maternal
buprenorphine dose for MAT and neonatal outcomes including
NOWS. Paralleling these results, we failed to identify a relationship between buprenorphine dose and NOWS. In our study
cohort, both the initial and ﬁnal buprenorphine dose was
similar among pregnancies with and without the occurrence
of NOWS requiring pharmacologic treatment.
As a strength of our study, it prospectively followed
patients receiving buprenorphine for MAT of OUD in pregnancy to evaluate the impact on maternal and neonatal
American Journal of Perinatology Reports
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outcomes, speciﬁcally NOWS. We also performed a detailed
evaluation of patterns of substance abuse in our study cohort
not only based on self-report but also ascertained through
objective metrics such as UDS testing. Urine drug testing was
performed throughout the course of pregnancy extending
through the 6-week postpartum study period, and also
included neonatal urine testing. Buprenorphine dosing was
also managed by a single provider with specialized training
and licensure with consultation provided as needed by an
addiction medicine psychiatrist.
This study has limitations—ﬁrst, we did not plan a priori to
test the effect of varying dose levels of buprenorphine on NOWS;
thus, we are unable to draw deﬁnitive conclusions about the
buprenorphine dose–response relationship with incident
NOWS. While the biologic plausibility of such a relationship

Buprenorphine Dose and Neonatal Opioid Withdrawal Syndrome
seems appropriate, the current data are inadequate in addressing
this question from an evidence-based standpoint. However, in
our study, the buprenorphine dose was titrated to administer the
most clinically appropriate dose on an individualized basis
factoring in patient symptomatology and drug response, medication compliance, and UDS results. Hence, we were unable to
speciﬁcally study the effect of varying dose levels. Similarly,
group comparisons were not planned according to a speciﬁed
level of statistical power, and post hoc power analysis is not
valid.30 Future studies in this area may beneﬁt from larger
sample sizes for more powerful group comparisons. Second,
alterations in buprenorphine dose were individualized, as
against adopting a protocolized approach. Given the sheer
paucity of data on alterations of buprenorphine metabolism
over the pregnancy time course, we chose to adopt an individualized approach to identify the dose that best suited each
patient’s needs. Lastly, we are unable to comment on a comparison with methadone, since this was beyond the scope of this
study. However, our data support the safety for adjusting the
antepartum buprenorphine dose as deemed clinically appropriate with minimal neonatal adverse effects. Interestingly, there
are inconsistent data regarding the relationship between
antenatal buprenorphine dose in pregnancy for MAT and the
severity of NOWS.21,25,26 In an attempt to elucidate the biologic
relationship between maternal buprenorphine and dose and
incident NOWS, previous research has examined the levels of
buprenorphine and its metabolites in the urine and meconium of
infants born to mothers receiving buprenorphine during pregnancy.31,32 However, these studies provide limited insights into
the plausibility of a relationship between antenatal buprenorphine dose and incident NOWS. In the light of these ﬁndings, our
study aimed at examining the relationship between buprenorphine dose and incident NOWS among pregnant patients
receiving buprenorphine for MAT of OUD during pregnancy.
Based on our data, we are not able to establish a diagnosis of a
relationship between buprenorphine dose in pregnancy and
subsequent NOWS. However, our results suggest that women
who are able to undergo MAT with buprenorphine in pregnancy
without the concurrent use of illicit opioids or benzodiazepines
are much less likely to have adverse neonatal outcomes as
compared with their counterparts. This is important information
for clinicians treating patients for OUD in pregnancy. Further
studies—particularly, larger randomized prospective trials—are
warranted to evaluate if a dose–response relationship exists
between antenatal buprenorphine dose and the occurrence and
severity of incident NOWS in pregnant patients undergoing
MAT of OUD.
Conﬂicts of Interest
Dr. Lofwall reports grants and consulting fees from Braeburn
Pharmaceuticals, consulting fees from Indivior, and honorarium from PCM Scientiﬁc, outside the submitted work.

Note
The abstract was presented at the 37th Annual Meeting
of the Society of Maternal Fetal Medicine in January 2017–
Abstract # 729.
Condensation
Examining the relationship between maternal buprenorphine dose for medication-assisted treatment of opioid
use disorder of pregnancy and the occurrence of neonatal
opioid withdrawal syndrome.

References
1 Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence

2

3

4

5

6

7

8

9

10

11

12
13

14

15

Financial Support
This research did not have speciﬁc ﬁnancial support.
Statement of Authorship
See attached documents.

Chavan et al.

16

syndrome after methadone or buprenorphine exposure. N Engl
J Med 2010;363(24):2320–2331
Kandall SR, Albin S, Gartner LM, Lee K-S, Eidelman A, Lowinson J.
The narcotic-dependent mother: fetal and neonatal consequences. Early Hum Dev 1977;1(02):159–169
Messinger DS, Bauer CR, Das A, et al. The maternal lifestyle study:
cognitive, motor, and behavioral outcomes of cocaine-exposed
and opiate-exposed infants through three years of age. Pediatrics
2004;113(06):1677–1685
Lifschitz MH, Wilson GS, Smith EO, Desmond MM. Factors affecting head growth and intellectual function in children of drug
addicts. Pediatrics 1985;75(02):269–274
Women ACoHCfU. ACOG Committee Opinion No. 524: opioid
abuse, dependence, and addiction in pregnancy. Obstet Anesthes
Dig 2013;33:79–80
Center for Substance Abuse Treatment. Improving Treatment for
Drug-Exposed Infants: Substance Abuse and Mental Health Services
Administration (US); 1993. Report No.: (SMA) 93–2011. https://www.
ncbi.nlm.nih.gov/pubmed/22514857. Accessed November 28, 2017
Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated
health care expenditures: United States, 2000-2009. JAMA 2012;
307(18):1934–1940
Jones HE, O’Grady KE, Malﬁ D, Tuten M. Methadone maintenance
vs. methadone taper during pregnancy: maternal and neonatal
outcomes. Am J Addict 2008;17(05):372–386
Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during
pregnancy. Effects and management. Obstet Gynecol Clin North
Am 1998;25(01):139–151
Dryden C, Young D, Hepburn M, Mactier H. Maternal methadone
use in pregnancy: factors associated with the development of
neonatal abstinence syndrome and implications for healthcare
resources. BJOG 2009;116(05):665–671
Cleary BJ, Donnelly J, Strawbridge J, et al. Methadone dose and
neonatal abstinence syndrome-systematic review and meta-analysis. Addiction 2010;105(12):2071–2084
Jansson LM, Velez M. Neonatal abstinence syndrome. Curr Opin
Pediatr 2012;24(02):252–258
Bakstad B, Sarﬁ M, Welle-Strand GK, Ravndal E. Opioid maintenance treatment during pregnancy: occurrence and severity of
neonatal abstinence syndrome. A national prospective study. Eur
Addict Res 2009;15(03):128–134
Finnegan LP, Connaughton JF Jr, Kron RE, Emich JP. Neonatal
abstinence syndrome: assessment and management. Addict Dis
1975;2(1-2):141–158
Jansson LM, Velez M, Harrow C. The opioid-exposed newborn:
assessment and pharmacologic management. J Opioid Manag
2009;5(01):47–55
Fudala PJ, Bridge TP, Herbert S, et al; Buprenorphine/Naloxone
Collaborative Study Group. Ofﬁce-based treatment of opiate
addiction with a sublingual-tablet formulation of buprenorphine
and naloxone. N Engl J Med 2003;349(10):949–958
American Journal of Perinatology Reports

Vol. 7

No. 4/2017

e221

e222

Buprenorphine Dose and Neonatal Opioid Withdrawal Syndrome

Chavan et al.

17 Johnson RE, Jones HE, Fischer G. Use of buprenorphine in preg-

25 Fischer G, Ortner R, Rohrmeister K, et al. Methadone versus

nancy: patient management and effects on the neonate. Drug
Alcohol Depend 2003;70(2, Suppl)S87–S101
Jones ES, Moore BA, Sindelar JL, O’Connor PG, Schottenfeld RS,
Fiellin DA. Cost analysis of clinic and ofﬁce-based treatment of
opioid dependence: results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend 2009;
99(1-3):132–140
Jones HE. Practical considerations for the clinical use of buprenorphine. Sci Pract Perspect 2004;2(02):4–20
Jones HE, Finnegan LP, Kaltenbach K. Methadone and buprenorphine for the management of opioid dependence in pregnancy.
Drugs 2012;72(06):747–757
Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus
methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol
Depend 2005;79(01):1–10
Jones HE, Fischer G, Heil SH, et al. Maternal Opioid Treatment:
Human Experimental Research (MOTHER)–approach, issues and
lessons learned. Addiction 2012;107(Suppl 1):28–35
Kakko J, Heilig M, Sarman I. Buprenorphine and methadone
treatment of opiate dependence during pregnancy: comparison
of fetal growth and neonatal outcomes in two consecutive case
series. Drug Alcohol Depend 2008;96(1-2):69–78
Welle-Strand GK, Skurtveit S, Jones HE, et al. Neonatal outcomes
following in utero exposure to methadone or buprenorphine: a
National Cohort Study of opioid-agonist treatment of Pregnant
Women in Norway from 1996 to 2009. Drug Alcohol Depend
2013;127(1-3):200–206

buprenorphine in pregnant addicts: a double-blind, doubledummy comparison study. Addiction 2006;101(02):275–281
Lejeune C, Simmat-Durand L, Gourarier L, Aubisson S; Groupe
d’Etudes Grossesse et Addictions (GEGA). Prospective multicenter
observational study of 260 infants born to 259 opiate-dependent
mothers on methadone or high-dose buprenophine substitution.
Drug Alcohol Depend 2006;82(03):250–257
Choo RE, Huestis MA, Schroeder JR, Shin AS, Jones HE. Neonatal
abstinence syndrome in methadone-exposed infants is altered by
level of prenatal tobacco exposure. Drug Alcohol Depend 2004;75
(03):253–260
Winklbaur B, Baewert A, Jagsch R, et al. Association between
prenatal tobacco exposure and outcome of neonates born to
opioid-maintained mothers. Implications for treatment. Eur Addict Res 2009;15(03):150–156
Jones HE, Dengler E, Garrison A, et al. Neonatal outcomes and their
relationship to maternal buprenorphine dose during pregnancy.
Drug Alcohol Depend 2014;134:414–417
Hoenig JM, Heisey DM. The abuse of power: the pervasive fallacy
of power calculations for data analysis. Am Stat 2001;55:19–24
Kacinko SL, Jones HE, Johnson RE, Choo RE, Huestis MA. Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes.
Clin Pharmacol Ther 2008;84(05):604–612
Hytinantti T, Kahila H, Renlund M, Järvenpää AL, Halmesmäki E,
Kivitie-Kallio S. Neonatal outcome of 58 infants exposed to
maternal buprenorphine in utero. Acta Paediatr 2008;97(08):
1040–1044

18

19
20

21

22

23

24

American Journal of Perinatology Reports

Vol. 7

No. 4/2017

26

27

28

29

30
31

32

